Cel-Sci Corp has revealed that in an animal model of human immunity, itsHGP-30 AIDS vaccine, which uses heteroconjugate technology, "confers high levels of protection against a different strain of HIV than the one from which HGP-30 is derived."
Heteroconjugate technology combines T cell binding ligands with disease-associated peptide antigens such as HGP-30, which "differs from other vaccines or immunogen candidates because it is a synthetic copy of a highly conserved part of the p17 core protein of the HIV virus," says the company.
HGP-30 has been tested in trials with 39 HIV-negative subjects and is currently in a separate study with 24 HIV-positive patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze